Metagenomics

Clinical Study Highlights Improvements to Gut Microbiome and Autism Spectrum Disorder Symptoms with Use of Custom Probiotics

Retrieved on: 
화요일, 5월 7, 2024
PGIA, Social Responsiveness Scale, ASU, Language, M-Systems, Arizona State University, Spectrum, Comprehension, Metagenomics, Health, Cognition, Thought, Trial of the century, Research, Speech, MTT, Diet, Probiotic, Caregiver, Genomics, Clinical trial, Quality of life, SAN, Dietary supplement

“Our research uncovered critical insight into the connection between precision nutrition – in the form of precision probiotics – and both gut health and autism spectrum disorder.

Key Points: 
  • “Our research uncovered critical insight into the connection between precision nutrition – in the form of precision probiotics – and both gut health and autism spectrum disorder.
  • The clinical research was conducted with the participation of 296 children and adults diagnosed with autism spectrum disorder and 123 age-matched neurotypical controls.
  • Behavioral and Autism Symptoms: Follow-up surveys revealed moderate improvement in thinking abilities, sensory experiences and overall autism-related symptoms among participants.
  • The next step is a randomized, double-blind and placebo-controlled study, which is needed to confirm the clinical study findings.

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
목요일, 5월 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
화요일, 4월 30, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, Research, VCF, Artificial intelligence, Dysbiosis, Personalized medicine, Multiomics, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

DUBAI, UAE, April 30, 2024 /PRNewswire/ -- BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and versatility, it promises to transform healthcare worldwide. The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

MGI Tech opens Customer Experience Center in Brazil to contribute to the advancement of genomics in Latin America

Retrieved on: 
일요일, 4월 28, 2024
Education, Agriculture, Genomics, BIT, Learning, Laboratory, CEC, Hospital, Metagenomics, Collection, Research, Megatron, Oswaldo Cruz Foundation, University, NGS, GenCell, Patient, Marker beacon, MGI, Next Generation, Genome, Diagnosis, Multimedia, Avenue, Medicine

SÃO PAULO, April 28, 2024 /PRNewswire/ -- Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil.  

Key Points: 
  • The agricultural sector can also benefit
    SÃO PAULO, April 28, 2024 /PRNewswire/ -- Contributing to the advancement of genomics in Latin America, MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, announced the launch of its Customer Experience Center (CEC) in Brazil.
  • "Our Customer Experience Center will be able to contribute significantly to the scientific development of the region by reducing sequencing costs, expanding clinical applications and, therefore, making precision diagnoses and treatments more accessible to the population", he adds.
  • The lab will also play a role as MGI Hub in Brazil, allowing the expansion of operations across Latin America.
  • MGI operates in 100 countries and has other 9 Customer Experience Centers around the world.

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
수요일, 4월 17, 2024
Research, Infectious Diseases, Neurology, Biotechnology, Other Health, Health, General Health, Other Science, Science, American Academy, GenePeeks, University, Cancer, Foundation Medicine, Genomics, DSM-IV codes, Infection, Bacteria, Fortune 500, Medical laboratory, Clear Labs, NGS, CLIA, Medicine, Encephalitis, UCSF, Ventricular septal defect, Patient, Meningitis, Parasitism, AAN, Physician, Immunodeficiency, Virus, Neuro, Fungus, CSF, Diagnosis, Neoplasm, Cerebrospinal fluid, Metagenomics, Pharmaceutical industry

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
목요일, 4월 25, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, AB, VCF, Research, Dysbiosis, Personalized medicine, Multiomics, Intelligence, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

Clinical Microbiomics Launches Advanced Long-Read 16S, ITS, 18S, Isolate, and Metagenomics Sequencing Services

Retrieved on: 
화요일, 4월 23, 2024
P24, ITS, Genomics, CCO, Metagenomics, Health, Probiotic, Business development, Nielsen, ONT, Research, Disease, DNA, Acquisition, Oxford Nanopore Technologies, Metabolomics, Prebiotic (nutrition), Algorithm

COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics, a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services. Tailored to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities, featuring the industry's highest quality scores and read lengths.

Key Points: 
  • COPENHAGEN, Denmark, April 23, 2024 /PRNewswire/ -- Clinical Microbiomics , a leader in microbiome analysis, announces the launch of its advanced long-read sequencing services.
  • Anders Grøn, CEO, states, "Our enhanced long-read sequencing capabilities are redefining the standards in microbial analysis and microbiome research.
  • Dr. Henrik Bjørn Nielsen , Chief Scientific Officer, states, "Our new long-read sequencing services represent a significant advancement in microbiome research.
  • Clinical Microbiomics' long-read sequencing services are globally available, supported by state-of-the-art laboratories in Denmark and the United States.

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Retrieved on: 
수요일, 3월 27, 2024
Research, Dicarboxylic acid, AAV, Enzyme, Development, Gene editing, CAST, Cardiovascular disease, Haemophilia, Vivisection, Patient, Primate, RNA, DNA, Wave 1, Sale, Metagenomics, G&A, IPO, Ultra, Doctor of Philosophy, Protein, MBA, Genome, SMART, Factor VIII, CRISPR, Amyloidosis, MGX, AGT, Liver, LNP, Ionis, PAM, Vaccine

EMERYVILLE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today reported financial results for the full year ended December 31, 2023, and additional business updates.

Key Points: 
  • The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, cash used to fund our operations was $91.4 million for the year ended December 31, 2023.
  • R&D Expenses: Research and development (R&D) expenses were $94.4 million for the full year ended December 31, 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $28.8 million for the full year ended December 31, 2023.

2024 Predictive Ag Report Warns Midwest Growers of Emerging Threats

Retrieved on: 
화요일, 3월 5, 2024
Soil, Data science, Metagenomics, Farmer, Index, Risk, Fusarium, Crop protection, Almanac, Pattern, DNA, Water, Agriculture

The 2024 Predictive Ag Report can be downloaded from Pattern Ag, the leading soil metagenomics company.

Key Points: 
  • The 2024 Predictive Ag Report can be downloaded from Pattern Ag, the leading soil metagenomics company.
  • EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Armed with the 2024 Predictive Ag Report, released today by Pattern Ag, corn and soybean farmers can unlock the full potential of their crops, boosting both yield and profitability.
  • Packed into the 2024 Predictive Ag Report, Pattern Ag unveils an Almanac pinpointing regions facing the highest risk of pest and pathogen outbreaks.
  • “This year’s Predictive Ag report builds upon last year’s report, uncovering other hidden yield robbers found in Midwest corn and soybean fields,” said Mike Tweedy, Vice President of Sales for Pattern Ag.

Global Metagenomic Market Research 2024-2028: A Game Changer in Diagnostics - New Technology Changes Viewpoint on Infections - ResearchAndMarkets.com

Retrieved on: 
금요일, 3월 1, 2024
Health Technology, Health, Medical Devices, Infection, Metagenomics, Chronic condition, Genetics, Genome, Genetic testing, Knowledge, Disease, Research report, Research, Cancer

The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Learn all about it in this new research report.
  • This report looks at the technology, the applications, the users and the types of products that will be sold.
  • Get our research team working for you by ordering all, or a portion, of this comprehensive report.